A Study of MPT-0118 as Monotherapy and in Combination with Pembrolizumab in Subjects With Advanced or Metastatic Refractory Solid Tumors

A Phase 1/1b Study of MPT-0118 in Subjects with Advanced or Metastatic Solid Tumors.

This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.

The study will be conducted in 3 parts:

  • Part A: MPT-0118 dose-escalation
  • Part B: MPT-0118 dose-escalation in combination with pembrolizumab
  • Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab

Inclusions/Exclusion: ECOG 0-1. Measurable disease by RECIST. PD after or on at least 1 systemic therapy in adv/mets setting. No prior tx with MALT1 inhibitor. No history of stroke, seizure disorder or myocarditis. No CNS, lepto, or brain mets. No HIV, or active HCV/HBV.

Learn More